業績

HOME > 業績

論文・学会発表

2017年

論文発表

  • Iwama E, Sakai K, Azuma K, Harada T, Harada D, Nosaki K, Hotta K, Ohyanagi F, Kurata T, Fukuhara T, Akamatsu H, Goto K, Shimose T, Kishimoto J, Nakanishi Y, Nishio K, Okamoto I.
  • Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
  • Annals of Oncology 28(1): 136-41
  • Takamori S, Toyokawa G, Okamoto I, Takada K, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Mukae N, Shoji F, Okamoto T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.
  • Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-Small-Cell Lung Cancer.
  • Anticancer Research 37(8): 4223-8
  • Tsubouchi K, Araya J, Minagawa S, Hara H, Ichikawa A, Saito N, Kadota T, Sato N, Yoshida M, Kurita Y, Kobayashi K, Ito S, Fujita Y, Utsumi H, Yanagisawa H, Hashimoto M, Wakui H, Yoshii Y, Ishikawa T, Numata T, Kaneko Y, Asano H, Yamashita M, Odaka M, Morikawa T, Nakayama K, Nakanishi Y, Kuwano K.
  • Azithromycin attenuates myofibroblast differentiation and lung fibrosis development through proteasomal degradation of NOX4.
  • Autophagy 13(8): 1420-34
  • Ogata-Suetsugu S, Yanagihara T, Hamada N, Ikeda-Harada C, Yokoyama T, Suzuki K, Kawaguchi T, Maeyama T, Kuwano K, Nakanishi Y
  • Amphiregulin suppresses epithelial cell apoptosis in lipopolysaccharide-induced lung injury in mice.
  • Biochemical and Biophysical Research Communications 484(2): 422-8
  • Mikumo H, Yanagihara T, Hamada N, Harada E, Ogata-Suetsugu S, Ikeda-Harada C, Arimura M, Suzuki K, Yokoyama T, Nakanishi Y
  • Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice.
  • Biochemical and Biophysical Research Communications 486(1): 205-9
  • Yanagihara T, Tomino T, Uruno T, Fukui Y
  • Thymic epithelial cell-specific deletion of Jmjd6 reduces aire protein expression and exacerbates disease development in a mouse model of autoimmune diabetes
  • Biochemical and Biophysical Research Communications 489(1): 8-13
  • Hamada N, Yanagihara T, Suzuki K, Ogata-Suetsugu S, Harada E, Mikumo H, Arimura-Omori M, Nakanishi Y
  • Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice.
  • Biochemical and Biophysical Research Communications 491(3): 656-61
  • Seki N, Kan-o K, Matsumoto K, Fukuyama S, Hamano S, Tonai K, Ota K, Inoue H, Nakanishi Y.
  • Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
  • Biochemical and Biophysical Research Communications 494(1-2): 242-8
  • Park J-H, Inoue H, Kato T, Zewde M, Miyamoto T, Matsuo Y, Salgia R, Nakamura Y.
  • TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
  • Cancer Sci 108(3): 488-96
  • Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.
  • Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
  • Cancer Science 108(9): 1843-9
  • Sakamoto C, Kohara H, Inoue H, Narusawa M, Ogawa Y, Hirose-Yotsuya L, Miyamoto S, Matsumura Y, Yamada K, Takahashi A, Tani K.
  • Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity.
  • Cancer Gene Ther 24(4):165-74
  • Kudo K, Hata J, Matsumoto K, Shundo Y, Fukuyama S, Inoue H, Kitazono T, Kiyohara Y, Ninomiya T, Nakanishi Y.
  • Association of Airflow Limitation with Carotid Atherosclerosis in a Japanese Community‐The Hisayama Study.
  • Circ J 81(12): 1846-53
  • Yoneshima Y, Morita S, Ando M, Miura S, Yoshioka H, Abe T, Kato T, Kondo M, Hosomi Y, Hotta K, Yamamoto N, Kishimoto J, Nakanishi Y, Nishio K. Okamoto I.
  • Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
  • Clinical Lung Cancer 18(1): 100-3
  • Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A, Kato T, Atagi S, Horinouchi H, Ando M, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakanishi Y, Okamoto I.
  • Treatment rationale and design for J-SONIC: a randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis.
  • Clinical Lung Cancer Epub ahead of print (Jun 20)
  • Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K.
  • A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
  • Clinical Lung Cancer 18(6): 719-23
  • Okamoto I, Schuette H, Stinchcombe T, Rodorigues-Pereira J, Antonio B, Chen J, Liu J, John W. Zinner R.
  • Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.
  • Current Medical Research and Opinion 33(5): 937-41
  • Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Tao L, Yu W, Khaznadar T, Tajima K, Shibata M, Seki A. Yamamoto N.
  • Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results.
  • Drug Safety Epub ahead of print (Oct 17)
  • Samukawa T, Matsumoto K, Tsukuya G, Koriyama C, Fukuyama S, Uchida A, Mizuno K, Miyahara H, Kiyohara Y, Ninomiya T, Inoue H.
  • Development of a self-scored persistent airflow obstruction screening questionnaire in a general Japanese population: the Hisayama study.
  • Int J Chron Obstruct Pulmon Dis 15(12): 1469-81
  • Hamano S, Matsumoto K, Tonai K, Fukuyama S, Kan-o K, Seki N, Inoue H, Nakanishi Y
  • Effects of corticosteroid plus long-acting beta2-agonist on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice.
  • Journal of Inflammation (Lond) 14: 2
  • Yokoyama T, Yanagihara T, K Suzuki, Hamada N, S Ogata-Suetsugu, K Tsubouchi, H Mikumo, C Ikeda-Harada, T Maeyama, Kuwano K, Nakanishi Y
  • Depletion of club cells attenuates bleomycin-induced lung injury and fibrosis in mice.
  • J Inflamm (Lond) 14: 20
  • Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatshu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I.
  • Alectinib for patients with ALK rearrangement-positive non-small cell lung cancer and a poor performance status (Lung Oncology Group in Kyushu 1401).
  • Journal of Thoracic Oncology 12(7): 1161-6
  • Hidaka N, Iwama E, Kubo N, Harada T, Miyawaki K, Tanaka K, Okamoto I, Baba E, Akashi K, Sasaki H, Nakanishi Y.
  • Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.
  • Lung Cancer 108: 75-82
  • Kawano Y, Iwama E, Tsuchihara K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y, Okamoto I.
  • CD44 variant-dependent regulation of redox balance in EGFR-mutation-positive non-small cell lung cancer: a target for treatment.
  • Lung Cancer 113: 72-78
  • Li C, Takeo M, Matsuda M, Nagai H, Xizheng S, Hatanaka W, Kishimura A, Inoue H, Tani K, Mori T, Katayama Y.
  • Facilitating the presentation of antigen peptides on dendritic cells for cancer immunotherapy using a polymer-based synthetic receptor.
  • Med Chem Commun 8:1207-12
  • Otsubo K, Goto H, Nishio M, Kawamura K, Yanagi S, Nishie W, Sasaki T, Maehama T, Nishina H, Mimori K, Nakano T, Shimizu H, Mak TW, Nakao K, Nakanishi Y, Suzuki A
  • MOB1-YAP1/TAZ-NKX2.1 axis controls bronchioalveolar cell differentiation, adhesion and tumour formation.
  • Oncogene 36(29): 4201-11
  • Kiyotani K, Park J-H, Inoue H, Husain A, Olugbile S, Zewde M, Nakamura Y, Vigneswaran WT.
  • Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma.
  • Oncoimmunology 6(2):e1278330
  • Yamamoto Y, Kiyohara C, Hamada N, Ogata-Suetsugu S, Nakanishi Y
  • Biological interaction of cigarette smoking on the association between genetic polymorphisms involved in inflammation and the risk of lung cancer: A case-control study in Japan.
  • Oncology Letters 13(5): 3873-81
  • Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I.
  • Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naive patients with non-small cell lung cancer harboring EGFR mutations.
  • Oncotarget 8(40): 68123-30
  • Ota K, Harada T, Otsubo K, Fujii A, Tsuchiya Y, Tanaka K, Okamoto I. Nakanishi Y.
  • Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay.
  • Oncotarget 8(42): 72127-32
  • Kawaguchi T, Yanagihara T, Yokoyama T, Saiko Suetsugu-Ogata, Hamada N, Chika Harada-Ikeda, Suzuki K, Maeyama T, Kuwano K, Nakanishi Y.
  • Probucol attenuates hyperoxia-induced lung injury in mice.
  • PLoS ONE 12(4): e0175129
  • Behler-Janbeck F, Takano T, Maus R, Stolper J, Jonigk D, Tort Tarres M, Fuehner T, Prasse A, Welte T, Timmer MS, Stocker BL, Nakanishi Y, Miyamoto T, Yamasaki S, Maus UA.
  • C-type Lectin Mincle Recognizes Glucosyl-diacylglycerol of Streptococcus pneumoniae and Plays a Protective Role in Pneumococcal Pneumonia.
  • PLoS Pathog 12(12): e1006038
  • Yoshida M, Kaneko Y, Ishimatsu A, Komori M, Iwanaga T, Inoue H.
  • Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma.
  • Pulmonary Pharmacology & Therapeutics 42: 7-12
  • Wakamatsu K, Nagata N, Kumazoe H, Oda K, Ishimoto H, Yoshimi M, Takata S, Hamada M, Koreeda Y, Takakura K, Ishizu M, Hara M, Ise S, Izumi M, Akasaki T, Maki S, Kawabata M, Mukae H, Kawasaki M.
  • Prognostic value of serial serum KL-6 measurements in patients with idiopathic pulmonary fibrosis.
  • Respiratory Investigation. 55(1): 16-23
  • Ogata-Suetsugu S, Hamada N, Takayama K, Tsubouchi K, Arimura-Omori M, Nakanishi Y
  • The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis.
  • Sarcoidosis Vasculitis and Diffuse Lung Diseases 34(1): 41-7
  • Takano T, Motozono C, Imai T, Sonoda K, Nakanishi Y, Yamasaki S
  • Dectin-1 intracellular domain determines species-specific ligand spectrum by modulating receptor sensitivity.
  • The Journal of Biological Chemistry 292(41): 16933-41
  • Kan-O K, Ramirez R, MacDonald MI, Rolph M, Rudd PA, Spann KM, Mahalingam S, Bardin PG, Thomas BJ
  • Human metapneumovirus infection in chronic obstructive pulmonary disease: impact of glucocorticosteroids and interferon.
  • The Journal of Infectious Diseases 215(10): 1536-45
  • Fukuda M, Shimada M, Kitazaki T, Nagashima S, Hashiguchi K, Ebi N, Takayama K, Nakanishi Y, Semba H, Harada T, Seto T, Okamoto I, Ichinose Y. Sugio K.
  • A phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu(LOGIK1004A).
  • Thoracic Cancer 8(1): 40-5
  • Yanagihara T, Ikematsu Y, Kato K, Yonekawa A, Ideishi S, Tochigi T, Sugio T, Miyawaki K, Tanaka K, Harada E, Hamada N, Nakanishi Y.
  • Expression of PD-1 and PD-L1 on cytotoxic T lymphocytes and immune deficiency in a patient with adult T cell leukemia/lymphoma.
  • Annals of Hematology Epub ahead of print (Oct 2)
  • Takeshita M, Anai S, Mishima S, Inoue K.
  • Coincidence of Immunotherapy-Associated Hemophagocytic Syndrome and Rapid Tumor Regression.
  • Annals of Oncology 28(1): 186-9
  • Yanagihara T, Tanaka K, Ota K, Kashiwagi E, Takeuchi A, Tatsugami K, Eto M, Nakanishi Y, Okamoto I
  • Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment.
  • Annals of Oncology 28(8): 2038-9
  • Otsubo K, Nakatomi K, Furukawa R, Ashida K, Yoneshima Y, Nakanishi Y, Okamoto I
  • Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab
  • Annals of Oncology 28(12): 3106-7
  • Ikematsu Y, Yoneshima Y, Ijichi K, Tanaka K, Harada T, Oda Y, Nakanishi Y. Okamoto I.
  • Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1.
  • Lung Cancer 112: 230-1
  • Yanagihara T, Hamano S, Otsubo K, Suzuki K, Hamada N, Matsumoto K, Nakanishi Y.
  • Acute respiratory failure in a healthy adult with human parvorirus B19 infection.
  • Open Journal of Clinical & Medical Case Reports 3(19): 1314
  • Ogata H, Okamoto I, Yoshimoto G, Obara T, Ijichi K, Iwama E, Harada T, Akashi K,  Nakanishi.
  • Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
  • Respiratory Investigation 55(2): 181-3
  • Mikumo H, Hamada H, Harada E, Yanagihara T, Ogata S, Yabuuchi H, Ijichi K, Takayama K, Nakanishi Y
  • A case of immunoglobulin G4-related respiratory disease with multiple lung cysts: A case report.
  • Respiratory Medicine Case Reports 21: 89-92
  • Rudd PA, Thomas BJ, Zaid A, MacDonald M, Kan-o K, Rolph MS, Soorneedi AR, Bardin PG, Mahalingam S
  • Role of human metapneumovirus and respiratory syncytial virus in asthma excerbations: where are we now?
  • Clinical Science 131(14): 1713-21
  • Ogata H, Yamamoto Y, Harada T, Nakanishi Y, Okamoto I, Iwama E, Kato K, Oda Y.
  • Severe aplastic anemia during osimertinib therapy in a patient with EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer.
  • Journal of Thoracic Oncology 12(5): e46-7
  • Imamura Y, Kawayama T, Kinoshita T, Sakazaki Y, Yoshida M, Takahashi K, Fujii K, Ando M, Hoshino T, Iwanaga T, Kohrogi H. Kyushu Asthma Seminar Investigators.
  • Poor pharmacological adherence to inhaled medicines compared with oral medicines in Japanese patients with asthma and chronic obstructive pulmonary disease.
  • Allergol Int 66(3): 482-4
  • 三雲大功
  • 大学病院の当科における医療・介護関連肺炎(NHCAP)に対するガレノキサシン(GRNX)の有効性と安全性の検討
  • 新薬と臨牀 66(2): 159-67
  • 緒方大聡、原田英治、今田悠介、三雲大功、濵田直樹、福山聡、中西洋一
  • スリガラス影よりCryptococcus neoformansが検出された 1例
  • 気管支学 39(1): 71-5
  • 有村雅子、河口知允、伊地知佳世、中島豊、継仁、出水みいる
  • 先端巨大症にEGFR遺伝子変異陽性肺癌を合併した1例
  • 日本呼吸器学会誌 6(1): 8-12
  • 緒方大聡、濵田直樹、山本宜男、岡本勇、松元幸一郎、中西洋一
  • 悪性黒色腫の治療中に発症したニボルマブによる薬剤性間質性肺炎の1例
  • 日本呼吸器学会誌 6(1): 32-6
  • 片平雄之、濵田直樹、山本悠造、緒方彩子、松元幸一郎、中西洋一
  • 間質性肺疾患が疑われた重症呼吸不全に対して体外式膜型人工肺を使用し救命できた1例
  • 日本呼吸器学会誌 6(1): 43-8
  • 田中謙太郎
  • がん薬物療法専門医講座「がん薬物療法専門医のための模擬テスト88」
  • 腫瘍内科 20(2): 179-80
  • 田中謙太郎
  • がん薬物療法専門医講座「がん薬物療法専門医のための模擬テスト88-解答と解説-」
  • 腫瘍内科 20(3): 253-7
  • 田中謙太郎、岡本勇
  • 進行期非小細胞肺癌における免疫チェックポイント阻害薬の可能性と課題
  • 日本内科学会雑誌 106(6): 1117-24
  • 濵田直樹、中西洋一
  • 特集/安全で効果的なステロイド療法ステロイド療法の効果的な使い方間質性肺炎・好酸球性肺炎
  • 臨牀と研究 94(7): 815-9
  • 田中謙太郎、Chen Dong
  • ステロイド受容体共活性化因子 steroid receptor coactivator (SRC)による Th17細胞の分化制御機構
  • 臨床免疫・アレルギー科 67(2): 133-9
  • 米嶋康臣、岡本勇
  • 特集/【肺がん-個別化医療の時代】非小細胞肺がんにおける免疫チェックポイント阻害剤
  • カレントテラピー 35(8): 743-9
  • 濵田直樹
  • 実臨床Q&A切除不能な進行・再発非小細胞肺がん:免疫チェックポイント阻害薬の適正使用~チーム iCIからみえてきたもの~Q3. 注意すべき副作用として間質性肺疾患が挙げられますが、その対策は?
  • Cancer Review 1(1): 42
  • 大田恵一、岡本勇
  • 実臨床Q&A切除不能な進行・再発非小細胞肺がん:免疫チェックポイント阻害薬の適正使用~チーム iCIからみえてきたもの~Q5. Pseudo progressionをどのように見極めるのでしょうか?
  • Cancer Review 1(1)
  • 野崎要、瀬戸貴司
  • 「肺がん診療ガイドライン 2016年版」改訂のポイント
  • Cancer Review 1(1)
  • 吉田誠
  • コラム/ディベート 9.喫煙の喘息への影響
  • 呼吸器疾患診断治療アプローチ1気管支喘息

学会発表

The American Academy of Allergy, Asthma & Immunology
The Impact of Chronic Sinusitis on Subjects Suffering from Persistent Cough.
野上裕子
American Thoracic Society International Conference 2017
C-type lectin Mincle recognizes glucosyl-diacylglycerol of Streptococcus pneumoniae and plays a protective role in pneumococcal pneumonia
髙野智嗣
American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib.
大坪孝平
第57回日本呼吸器学会学術講演会
会長特別企画シンポジウム
呼吸器領域におけるトランスレーショナルリサーチの展開「肺癌2(サラゾピリン併用)」
大坪孝平
会長特別企画シンポジウム
免疫チェックポイント阻害薬と肺合併症「チーム医療による免疫チェックポイント阻害薬のマネージメント」
岡本勇
教育講演
吸入薬のデバイスとその使い分け
古藤洋
ランチョンセミナー
免疫チェックポイント阻害剤導入による進行非小細胞肺癌治療体系のパラダイムシフト
岡本勇
第21回日本がん分子標的治療学会学術集会
シンポジウム
がん分子標的治療薬の新たな展開-Best-in-classとFirst-in-classアプローチの対比-「EGFR-TKIsのfirst-in-classとbest-in-class」
岡本勇
第15回日本臨床腫瘍学会学術集会
ASCO/JSMO Joint symposium
Combination therapy with molecularly targeted agents in lung cancer.
岡本勇
シンポジウム
免疫チェックポイント阻害薬の副作用とその対策「チーム医療による免疫チェックポイント阻害薬の副作用マネージメント」
岡本勇
教育講演
肺癌の薬物療法
岡本勇
第88回日本呼吸器学会近畿地方会/第118回日本結核病学会近畿地方会
ランチョンセミナー
免疫チェックポイント阻害剤の使いどころと毒性マネージメント
岡本勇
第57回日本肺癌学会九州支部会学術集会/第40回日本呼吸器内視鏡学会九州支部総会
ランチョンセミナー
新たなエビデンスに基づく進行非小細胞肺癌の標準治療~最新の肺癌診療ガイドラインにどう反映されたか~
岡本勇
第79回日本呼吸器学会・日本結核病学会・日本サルコイドーシス/肉芽腫性疾患学会九州支部秋季学術講演会
シンポジウム
間質性肺疾患:さらなる病態の理解と治療への展望 喫煙関連呼吸器難病に対する前向きコホート研究
濵田直樹